| Studies (febrile neutropenic episodes) | Prevalence of adverse outcome (range) | Sensitivity for adverse outcome (range) | Specificity for adverse outcome (range) | LR + (range) | LR - (range) | References |
|---|---|---|---|---|---|---|
| MASCC score (<21) in adults for the prediction of adverse outcome | ||||||
| 8 (1951) | 5% to 62% | 40% to 88% | 59% to 95% | 2.11 to 11.21 | 0.14 to 0.66 | Ahn (2010),Baskaran (2010), Carmona-Bayonas (2011), Cherif (2006), De Souza Viana ( 2008), Hui (2010), Innes (2008) and Klastersky (2006) |
| Klaassen rule | ||||||
| 6 (3218) | 4% to 29% | 37% to 100% | 23% to 58% | 0.88 to 1.69 | 0 to 1.08 | Phillips, et al., (2010), Amman, et al., (2010) and Macher, et al., (2009) |
| Ammann rule | ||||||
| 3 (1038) | 17% to 37% | 95% to 100% | 9% to 22% | 1.05 to 1.29 | 0 to 0.52 | Phillips, et al., (2010), Amman, et al., (2010) and Macher, et al .,(2009) |
| PINDA rule | ||||||
| 4 (1342) | 16% to 53% | 67% to 93% | 20% to 76% | 1.15 to 3.91 | 0.10 to 0.69 | Phillips, et al., (2010), Amman, et al., (2010) and Macher, et al., (2009) |
| Alexander rule | ||||||
| 3 (1278) | 14% to 29% | 59% to 94% | 9% to 65% | 1.03 to 2.39 | 0.24 to 0.71 | Phillips, et al., (2010), Amman, et al., (2010) and Dommett, et al., (2009) |
From: Identification and Assessment: guideline chapter four
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.